Clinical Trial Update: A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of a subcutaneous formulation of efgartigimod in adults with Chronic Inflammatory Demyelinating Polyneuropath…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Status: COMPLETED | Results posted: 2024-08-20